Madan Gopal Kundu

Madan Gopal Kundu

Auto-generated profile, based on publicly available information

Madan Gopal Kundu

AbbVie, North Chicago, Illinois, USA

Research Focus & Metrics

Academic Career Length

11Years (2016-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 July 2022 in Neuro-Oncology
Verified
Journal Article
Open access
PDF file
ALAndrew B Lassman
Andrew B Lassman
SPStephanie L Pugh
Stephanie L Pugh
TWTony J C Wang
Tony J C Wang
KAKenneth Aldape
Kenneth Aldape
HGHui K Gan
Hui K Gan
MMMinesh P Mehta
Minesh P Mehta
Approximately 50% of newly diagnosed glioblastomas (GBMs) harbor epidermal growth factor receptor gene amplification (EGFR-amp). Preclinical and early-phase clinical data suggested efficacy of depatuxizumab mafodotin (depatux-m), an antibody–drug conjugate comprised of a monoclonal antibody that binds activated EGFR (overexpressed wild-type and EGFRvIII-mutant) linked to a microtubule-inhibitor toxin in EGFR-amp GBMs. In this phase III trial, adults with centrally confirmed, EGFR-amp newly diagnosed GBM were randomized 1:1 to radiotherapy, temozolomide, and depatux-m/placebo. Corneal epitheliopathy was treated with a combination of protocol-specified prophylactic and supportive measures. There was 85% power to detect a hazard ratio (HR) ≤0.75 for overall survival (OS) at a 2.5% 1-sided significance level (ie traditional two-sided p ≤ 0.05) by log-rank testing. There were 639 randomized patients (median age 60, range 22–84; 62% men). Prespecified interim analysis found no improvement in OS for depatux-m over placebo (median 18.9 vs. 18.7 months, HR 1.02, 95% CI 0.82–1.26, 1-sided p = 0.63). Progression-free survival was longer for depatux-m than placebo (median 8.0 vs. 6.3 months; HR 0.84, 95% confidence interval [CI] 0.70–1.01, p = 0.029), particularly among those with EGFRvIII-mutant (median 8.3 vs. 5.9 months, HR 0.72, 95% CI 0.56–0.93, 1-sided p = 0.002) or MGMT unmethylated (HR 0.77, 95% CI 0.61–0.97; 1-sided p = 0.012) tumors but without an OS improvement. Corneal epitheliopathy occurred in 94% of depatux-m-treated patients (61% grade 3–4), causing 12% to discontinue. Interim analysis demonstrated no OS benefit for depatux-m in treating EGFR-amp newly diagnosed GBM. No new important safety risks were identified.

4 January 2024 in Journal of Occupational Health
Verified
Journal Article
Open access
SMSukhDev Mishra
SukhDev Mishra
GAG Avinash
G Avinash
MKMadan G Kundu
Madan G Kundu
JVJyotsna Verma
Jyotsna Verma
ASAnkit Sheth
Ankit Sheth
ADAbhijit Dutta
Abhijit Dutta
Objectives: Work-related musculoskeletal disorders (WMSDs) are among the most common occupational diseases, affecting various sectors such as agriculture, small-scale industries, handicrafts, construction, and banking. These disorders, caused by overexertion and repetitive motion, lead to work absenteeism, productivity loss, and economic impacts. The aim of the study was to determine the magnitude of musculoskeletal disorders among different occupational workers in India. Methods: We identified studies reporting the prevalence of WMSDs using the Nordic Musculoskeletal Questionnaire in different databases between 2005 and 2023 through searches on SCOPUS, PubMed Central, and Google Scholar. The required information was then extracted. A random effects model was used to pool estimates of prevalence with 95% CIs. Publication bias was assessed by applying funnel plots. Results: The 12-month prevalence of WMSDs was reported across several occupational groups, and the meta or the pooled prevalence was estimated as 0.76 (95% CI, 0.70 to 0.82) along with substantial variability in the prevalence estimates between different industries and studies. The meta-prevalence for low back pain was estimated as 0.60 (95% CI, 0.54 to 0.66). The meta-prevalence for neck pain was estimated as 0.40 (95% CI, 0.34 to 0.47) whereas for shoulder pain it was estimated as 0.36 (95% CI, 0.30 to 0.42), respectively. The risk of bias was statistically nonsignificant, and overall publication bias was low as per visual inspections from funnel plots. Conclusions: WMSDs are prevalent across various Indian industries in significant proportions, particularly in agriculture, health care, and mining, leading to significant productivity loss and economic impact. The variation in prevalence highlights the need for sector-specific interventions. Addressing WMSDs requires comprehensive ergonomic and policy measures. Effective strategies are essential to mitigate these disorders’ widespread impact.

4 February 2022 in Clinical Lung Cancer
Verified
Journal Article
Open access
RGRamaswamy Govindan
Ramaswamy Govindan
MLMike Lind
Mike Lind
AIAmelia Insa
Amelia Insa
SKSaad A. Khan
Saad A. Khan
DUDmitry Uskov
Dmitry Uskov
BBBruce A. Bach
Bruce A. Bach
This open-label Phase III trial (NCT02264990) evaluated the PARP inhibitor, veliparib, combined with carboplatin/paclitaxel versus chemotherapy alone for first-line treatment of patients with advanced non-squamous non-small cell lung cancers (NSCLC). A 52-gene expression classifier (LP52) previously shown to identify patients more likely to respond to veliparib was evaluated as a planned correlative analysis. Adult current or former smokers with advanced non-squamous NSCLC were randomized 1:1 to veliparib (120 mg daily for 7 days/cycle) with carboplatin and paclitaxel or to investigators' choice of platinum doublet chemotherapy (up to 6, 21-day cycles), with optional pemetrexed maintenance. Prospective analysis of the LP52 signature was conducted using a clinical Qiagen/HTG assay. The primary endpoint was overall survival (OS) in LP52+ patients. Overall, 595 patients received veliparib + carboplatin/paclitaxel (n = 298) or chemotherapy alone (n = 297); 13% (n = 40) in each arm were LP52+. The primary endpoint was not met; median OS was 11.2 months with veliparib + carboplatin/paclitaxel versus 9.2 months with chemotherapy alone in the LP52+ subgroup (hazard ratio [HR] 0.644, 95% confidence interval [CI]: 0.396-1.048; P = .113). In the overall population, median OS was 12.1 months in both arms (HR 0.986, 95% CI: 0.827-1.176; P = .846). No new safety signals were observed. In patients with non-squamous NSCLC, there was no significant improvement in OS with veliparib + carboplatin/paclitaxel versus chemotherapy alone, although a trend toward improved OS in the LP52+ population suggests this subgroup may benefit from veliparib. Statistical power was limited due to the small sample size.


31 December 2018 in Biostatistics & Epidemiology
Verified
Journal Article
Closed access
MKMadan Gopal Kundu
Madan Gopal Kundu
Jaroslaw HarezlakJaroslaw Harezlak
Jaroslaw Harezlak
Longitudinal changes in a population of interest are often heterogeneous and influenced by a combination of baseline factors. In such cases, classical linear mixed effects models [Laird NM, Ware JH. Random-effects models for longitudinal data. Biometrics. 1982;38:963–974.] for the mean structure provide poor fit to the data. We propose regression tree methodology for the longitudinal data identifying and characterizing homogeneous subgroups. Currently available regression tree construction methods are either limited to a repeated measures scenario or combine the heterogeneity among subgroups with the random inter-subject variability. We propose a longitudinal classification and regression tree (LongCART) algorithm under conditional inference framework that overcomes these limitations utilizing a two-step approach. The LongCART first selects the partitioning variable via a parameter instability test and then finds the optimal split for the selected partitioning variable. Thus, at each node, the decision of further splitting is type I error controlled, guarding against variable selection bias, over-fitting and spurious splitting. We obtained asymptotic results for the proposed instability test and examined its finite sample behavior through simulation studies. Comparative performance of LongCART algorithm was evaluated empirically via simulation studies. Finally, we applied LongCART to study the longitudinal changes in choline levels among HIV-positive patients.

26 June 2023 in Clinical Cancer Research
Verified
Journal Article
Open access
PDF file
SGSuzanne George
Suzanne George
MHMichael C. Heinrich
Michael C. Heinrich
NSNeeta Somaiah
Neeta Somaiah
POPeter Oppelt
Peter Oppelt
RMRobert McLeod
Robert McLeod
YNYoichi Naito
Yoichi Naito
Purpose: To evaluate DS-6157a, an antibody–drug conjugate targeting G protein–coupled receptor 20 (GPR20), in gastrointestinal stromal tumors (GIST). Patients and Methods: In this phase I multicenter, open-label, multiple-dose study, patients with previously treated advanced GIST received intravenous DS-6157a on Day 1 of 21-day cycles, with a starting dose of 1.6 mg/kg. The primary objective evaluated the safety and tolerability of DS-6157a, while determining dose-limiting toxicity (DLT) and the MTD. Secondary objectives included plasma pharmacokinetics parameters, plasma antidrug antibodies (ADA), and efficacy. Results: A total of 34 patients enrolled. DS-6157a was well tolerated, with DLTs in 4 patients (11.8%) at doses of 6.4 mg/kg, 9.6 mg/kg, and 12.8 mg/kg; the MTD was determined to be 6.4 mg/kg. Treatment-emergent adverse events (TEAE) grade ≥3 occurred in 17 patients (50.0%), including decreased platelet count (23.5%), anemia (20.6%), decreased neutrophil count (14.7%), and decreased white blood cell count (11.8%). Four patients (11.8%) experienced serious adverse events related to DS-6157a. Six patients died with 5 due to disease progression and 1 due to DS-6157a-related TEAE. Tumor shrinkage was observed in 7 patients (20.6%), and 1 patient (2.9%) achieved a partial response. Plasma concentrations and exposure of intact DS-6157a, DXd, and total anti-GPR20 antibody all demonstrated a dose-dependent profile. No treatment-emergent ADAs were observed. Conclusions: Targeting GPR20 with DS-6157a was tolerated in patients with advanced GIST with tumor shrinkage demonstrated in KIT/PDGFRA wild-type GIST. However, the study did not proceed further due to lower efficacy outcomes than anticipated.